The effect of endogenous opioid peptides and their synthetic analogs on T-cell immunity
Korostelev SA, Isakova KL, Shchegolev AI, Uteshev BS · 1994 · Eksp Klin Farmakol. 1994;57(1):57-61. PMID 8142868
This source appears in the Thymalin–Dalargin evidence review. A single-agent experiment, comparative study or patent alternative is not automatically a combined-treatment trial.
Reported findings and study design
Narrative findings; numerical extraction incomplete
The abstract describes an opioid-class stimulation maximum when added 24–48 hours after culture initiation under suboptimal antigen conditions. It does not isolate a quantitative Dalargin-specific maximum.
Alloantigen-stimulated mixed-lymphocyte cultures; species, sample counts and quantitative Dalargin-specific response unresolved in the abstract.
Dose, route and schedule
The abstract describes opioid addition 24–48 hours after culture initiation for a class-level maximum; Dalargin-specific concentration and timing are not fully resolved.
Protocol source ↗ · Original indexed abstract; historical research methods
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Timing-dependent culture response | Largest opioid-class stimulation described after addition at 24–48 hours | Class-level statement under suboptimal antigen conditions; not a Dalargin-specific human schedule |
| Ligand differences | Selective mu- and delta-ligands had effects in different directions | DAGO and DADLE findings are not assigned to Dalargin |
| Dalargin-specific quantitative gap | No separate numerical Dalargin effect or concentration table provided |
Findings apply to this preparation, assay and comparison. They do not establish Thymalin–Dalargin combination efficacy or a safe combined regimen.
Source for the extracted data ↗ · Checked 2026-11-08
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- Concentrations, denominators, uncertainty and precise ligand-specific contrasts require the full paper.
- Culture timing is not a clinical administration schedule and does not establish Thymalin combination benefit.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Document format: Original indexed abstract
Review depth: Indexed abstract and citation checked; full original outcome tables not recovered
Source access and review scope
Original PubMed / Europe PMC indexed abstract checked. Missing group sizes, doses, raw outcomes and uncertainty are not reconstructed.
Recorded source-check date: 2026-11-08. This date does not imply a completed systematic review.
Source type: Original journal publication
Citation and original source
Original source: Korostelev SA, Isakova KL, Shchegolev AI, Uteshev BS. The effect of endogenous opioid peptides and their synthetic analogs on T-cell immunity Eksp Klin Farmakol. 1994;57(1):57-61. PMID 8142868 1994.
Molekul research summary: https://molekul.io/research/dalargin-t-cell-cytotoxicity-1994. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry